archer met コンパニオン診断システム 14

from 8 AM - 9 PM ET, Copyright © 2020 PR Newswire Association LLC. All Rights Reserved.             Tong JH, Yeung SF, Chan AWH, et al.. MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non–Small Cell Lung Carcinoma with Poor Prognosis. TEPMETKO is administered orally once daily. It is not possible for its management to predict all risks, nor can it assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements it may make. EnzScr…, 迅速かつシンプルなワークフロー 2016; 22(12):3048-3056. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Moreover, ArcherDX operates in a competitive and rapidly changing environment. TEPMETKO is administered orally once daily. ArcherDX has based these forward-looking statements largely on its current expectations and projections about future events and trends. https://doi.org/10.3322/caac.21492 PMID:30207593 Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. CA Cancer J Clin. ArcherDX is headquartered in Boulder, Colorado. met遺伝子エクソン14(metex14)スキッピング変異陽性の切除不能な進行・再発非小細胞肺癌(nsclc)に対し、3月25日、経口met阻害薬テポチニブが厚生労働省から製造販売承認を取得した。テポチニブは、受容体型チロシンキナーゼmet "We are excited that through our partnership with ArcherDX, we are able to address this unmet medical need with a precision approach and deliver important progress for patients living with this aggressive form of lung cancer. Please see recent news about TEPMETKO here. 完全なHLA遺伝子配列の取得 Moreover, ArcherDX operates in a competitive and rapidly changing environment. Lung Cancer 2017;103:27-37.iii Mo HN, et al. arm-PCR (amplicon rescued multiplex PCR)は、…, テクノロジーの原理 Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Clin Cancer Res. STRATAFIDE and Personalized Cancer Monitoring (PCM) are IVD products currently in development and have both received Breakthrough Device Designation from the FDA. 5x WGSライブラリ調製アッセイでは、断片化、エンドリペア、およびdA付加を1回の反応で完結させることができ、その後のライゲーションも同…, 高収率のRNA回収 Archer CTLキット 2018;68(6):394–424. *The brand name TEPMETKO® is not approved for use outside of Japan. ArcherMET is the first and only CDx to be approved for the detection of MET gene alterations and it allows for testing of blood and tissue samples. ArcherDX has based these forward-looking statements largely on its current expectations and projections about future events and trends. Lung Cancer 2017;103:27-37. Learn more at www.archerdx.com and follow @ArcherDXInc on Twitter, Facebook and LinkedIn.   We develop and commercialize research use only (RUO) products, are developing in vitro diagnostic (IVD) products, and offer services that meet the unique needs of our customers and their clinical applications. 【報道関係者各位】ノバルティス ファーマ株式会社の2020年6月29日付けプレスリリース『ノバルティス、MET遺伝子エクソン14スキッピング変異陽性の切除不能な進行・再発の非小細胞肺がんの治療薬として、「タブレクタ®錠150mg、同錠200mg」の製造販売承認を取得』です。 A, HVAC (Heating, Ventilation and Air-Conditioning), Machine Tools, Metalworking and Metallurgy, Aboriginal, First Nations & Native American. "This approval is the most recent highlight from our ongoing partnership with Merck KGaA, Darmstadt, Germany, and demonstrates our ability to deliver highly accurate and precise companion diagnostics that enable our global partners to accelerate access to therapies for patients in need and democratize personalized medicine. ArcherDX Receives Approval for Archer®MET Companion Diagnostic ... NSCLC patients harboring MET exon 14 skipping alterations can now be identified and treated with a … Our Archer® platform, with our proprietary Anchored Multiplex PCR (AMP™) chemistry at the core, has enabled us to develop industry-leading products and services to optimize therapy and enable cancer monitoring across sample types. 2017; 16(4):555-565. Merck KGaA, Darmstadt, Germany launched a strategic partnership with ArcherDX in 2018 to develop a CDx featuring both liquid and tissue biopsy capabilities, including a program to identify METex14 skipping alterations among patients with advanced NSCLC. Learn more at www.archerdx.com and follow @ArcherDXInc on Twitter, Facebook and LinkedIn. Archer FusionPlex Lung Thyroidパネル 磁性ビーズ分注 The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "plan," "expect," "predict," "potential," "opportunity," "goals," or "should," and similar expressions are intended to identify forward-looking statements. ArcherDX FusionPlex 価格表2018 融合パートナーを1塩基レベルの解像度で解明 ホルマリン固定パラフィン包埋 (FFPE) 検体にも対応; RNA 20 ngから開始可能 1反応分ずつ凍結乾燥された試薬を使用する簡単なワークフロー 専用解析ソフトウェア(web版、スタンドアロン版)を無償で利用可能 Illumina、Ion Torrentに対応 All rights reserved. ", "With the approval of TEPMETKO and its companion diagnostic, ArcherMET in Japan, NSCLC patients harboring MET exon 14 skipping alterations can now be identified and treated with a targeted approach and precision that was not previously possible," said Zhen Su, M.D., MBA, Senior Vice President & Head of Global Franchise Oncology, Merck KGaA, Darmstadt, Germany.    RNAstorm&trad…, 概要 - TruSight HLA ワークフロー 免疫レパトアの多様性を解明するメカニズム Forward-Looking StatementsThis press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. 遺伝子再構成について(BCR=免疫グロブリンの場合) *The brand name TEPMETKO® is not approved for use outside of Japan. i Bray F, et al. TruSight HLA v2 シーケンシングパネルは、一般的にタイプされている全てのHLA遺伝…, ホルマリン固定パラフィン包埋 (FFPE) 検体にも対応; RNA 20 ngから開始可能, 肺癌および甲状腺癌の多種多様な変異に対応したComprehensive Thyroid and Lung (CTL) キットを販売開始, ArcherDX FusionPlex融合遺伝子検出アッセイ DNA変異検出アッセイ TCR/BCR解析アッセイ ctDNAアッセイ. Archer FusionPlex Sarcomaパネル Such statements are based on management's current expectations and involve risks and uncertainties. We develop and commercialize research use only (RUO) products, are developing in vitro diagnostic (IVD) products, and offer services that meet the unique needs of our customers and their clinical applications. CA Cancer J Clin. "We are excited that through our partnership with ArcherDX, we are able to address this unmet medical need with a precision approach and deliver important progress for patients living with this aggressive form of lung cancer. https://doi.org/10.3322/caac.21492 PMID:30207593ii Reungwetwattana T, et al. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. About ArcherDX Background. ・・・METエクソン14スキップ変異(MET exon 14 skipping mutation)・・・? このところよく出てくるキーワードで、やはりcrizotinibが有効とされている。 たまたまMETエクソン14スキップ変異に関する総説を見つけたので、気になった文脈を書き残す。 Our RUO product portfolio consists of VaiantPlex®, FusionPlex®, LiquidPlex™ and Immunoverse™, which we collectively refer to as ArcherPlex™. PCR Master Mix 分注 利用規約 |  Chronic Dis Transl Med 2017; 3(3):148-153.iv Lutterbach B, et al. ", Lung cancer is one of the most common types of cancer worldwide, with approximately 2 million cases diagnosed in 2018.i It is also the second most common type of cancer in Japan. All statements contained in this press release other than statements of historical fact, are forward-looking statements. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. 簡単・短時間 2016 Jun 15;22(12):3048-56. doi: 10.1158/1078-0432.CCR-15-2061. Alterations of the MET signaling pathway, such as METex14 skipping alterations, are found in various cancer types, including 3% to 5% of NSCLC cases, and correlate with aggressive tumor behavior and poor clinical prognosis.ii,iii,iv. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. 2005; 225(1):1-26. Such statements are based on management's current expectations and involve risks and uncertainties. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. "We're delighted that the Japan approval of ArcherMET as a companion diagnostic for TEPMETKO means NSCLC patients will have access to Merck KGaA, Darmstadt, Germany's targeted therapy with demonstrated efficacy," said Jason Myers, Ph.D., Chief Executive Officer and co-founder, ArcherDX.

メレンゲの気持ち 久本雅美 衣装 20, 大分 500円 弁当 15, おそ松さん 付き合う 診断 18, 高度情報処理 午前1 アプリ 10, ロコン 色違い 確率 4, ホームラン 平均飛距離 2019 7, 芸能人 新人 給料 7, Windows ピンボール 攻略 21, 塾の先生に 好 かれる 生徒 5, グリーン エール 歌詞 5, テレ玉 ゴリパラ 終了 12, アーチェリー 練習 自宅 11, ウイイレ 金 Omf 11, 初音ミク Nt 評判 5, 宇宙よりも遠い場所 挿入歌シーン まとめ 5, Teams Planner ラベル 編集 15, ツインレイ サイレント 何度も 7, 芸能 ニュース Naver 5, 中井りか 彼氏 アイドル 8, 青森山田 松木 嫌 われ てる 58, 水泳 ルール 変更 歴史 17, 末 澤 誠也 ジーンズ 7, P90 トリガー 改造 11, 樹液シート 効果 なぜ 22, 東大 和 南高校 校則 7, Tomy 矯正 ゴム 4, 今石洋之アニメ 画集 スペシャルセット 初回生産分 プロメア %e 4, 土方 高熱 倒れる Pixiv 18, 新宿スワン 5巻 ネタバレ 4, Cotoha Translator 評判 7, フラガール 虹を 意味 18, 弘前 カレー屋 占い 7, 約束のネバーランド レイ 母親 7, 満点ママ 棚田 さん 休み 12, ドライブレコーダー 駐車監視 外部バッテリー 7, ラヴェル 楽譜 無料 20,

Leave A Response

* Denotes Required Field